Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 19, Issue 12, Pages -Publisher
SPRINGER
DOI: 10.1007/s11864-018-0593-2
Keywords
Programmed death ligand-1; Immunotherapy; Gynecologic cancer; Ovarian cancer; Endometrial cancer; Cervical cancer
Categories
Ask authors/readers for more resources
Opinion statementActivity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available